ENA Respiratory, a clinical-stage pharmaceutical company developing host defence enhancers for the prevention of complications associated with respiratory viral infections in at-risk populations, has dosed the first participants in part B of its phase 2a community study of INNA-051.
INNA-051 is a virus-agnostic, once-weekly, dry powder nasal spray that primes the natural antiviral host defences in the nose where common respiratory viruses like rhinovirus, flu, RSV and coronaviruses primarily enter. This enables the body to respond more quickly when challenged.
INNA-051 therapy aims to reduce the incidence of complications in patients at higher risk of severe illness.
The study is evaluating the safety, tolerability and efficacy of up to three months’ treatment with INNA-051 and assessing its impact on the incidence, duration and severity of symptomatic infections caused by common respiratory viruses in young adult participants at risk of illness due to living or working in crowded environments.
Part A of the study was successfully completed in 200 participants in May with no safety concerns identified following four weeks of weekly dosing.
Part B will recruit up to 900 participants during this North American respiratory virus season, with participants dosed for three months across five sites in the USA.
